Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients

Transplantation

Volumn 80, Issue 1, 2005, Pages 118-126

  Van Kampen, Corine A ^a   Van De Linde, Pieter ^a   Duinkerken, Gaby ^a   Van Schip, Jolien J ^a   Roelen, Dave L ^a   Keymeulen, Bart ^b,c   Pipeleers, Daniel G ^b,c   Claas, Frans H J ^a   Roep, Bart O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c JDRF Center for Beta Cell Therapy in Europe   (Belgium)

Author keywords

Alloreactivity; Diabetes; Islet transplantation; Tolerance

Indexed keywords

ALLOIMMUNITY; ALLOTRANSPLANTATION; ARTICLE; CASE REPORT; CELL FUNCTION; CYTOTOXIC T LYMPHOCYTE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANTILYMPHOCYTE SERUM; AUTOIMMUNITY; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; ISOANTIBODIES; POSTOPERATIVE PERIOD; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UREMIA;

EID: 22144445286     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000164143.22287.E3     Document Type: Article

References (31)

1. Scharp DW, Lacy PE, Santiago JV, et al. Results of our first nine intraportal islet allografts in type I, insulin-dependent diabetic patients. Transplantation 1991; 51: 76.
2. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
3. Warnock GL, Kneteman NM, Ryan EA, et al. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type I (insulin -dependent) diabetes mellitus. Diabetologia 1992; 35: 89.
4. Ricordi C, Tzakis AG, Carroll PB, et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992; 53: 407.
5. Gores PF, Najarian JS, Stephanian E, et al. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993; 341; 19.
6. Secchi A, Socci C, Maffi P, et al. Islet transplantation in IDDM patients. Diabetologia 1997; 40: 225.
7. Hering BJ, Browatzki CC, Schultz A, et al. Clinical islet transplantation-registry report, accomplishments in the past and future research needs. Cell Transplant 1993; 2: 269.
8. Soon-Shiong P, Heintz RE, Merideth N, et al. Insulin independence in a type I diabetic patient after encapsulated islet transplantation. Lancet 1994; 343: 950.
9. Shapiro A, Hao EG, Lakey JRT, et al. Novel approaches toward early diagnosis of islet allograft rejection. Transplantation 2001; 71: 1709.
10. Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362.
11. Tyden G, Reinholt FP, Sundkvist G, et al. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. New England Journal of Medicine 1996; 335: 860.
12. Sibley RK, Sutherland DE, Goetz F, et al. Recurrent diabetes mellitus in the pancreas iso-and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Laboratory Investigation 1985; 53: 132.
13. Rakotoambinina B, Timsit J, Deschamps I, et al. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Diabetes Care 1995; 18: 1487.
14. Keymeulen B, Ling Z, Gorus FK, et al. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998; 41: 452.
15. Roep BO, Stobbe I, Duinkerken G, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type I diabetic patients. Diabetes 1999; 48: 484.
16. Stobbe I, Duinkerken G, van Rood JJ, et al. Tolerance to kidney allograft transplanted into type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismtaches. Diabetologia 1999; 42: 1379.
17. Movahedi B, Keymeulen B, Lauwers MH, et al. Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients. Transplant International 2003; 16: 186.
18. Bouma GJ, van der Meer-Prins EMW, van Bree FMPJ, et al. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a non-radioactive alternative to labeling with chromium-51. Human Immunology 1992; 35: 85.
19. Strijbosch LWG, Buurman WA, Does RJMM, et al. Limiting dilution assays; experimental design and statistical analysis. Journal of Immunological Methods 1987; 97: 133.
20. Zhang L, Li SG, Vandekerckhove B, et al. Analysis of cytotoxic T cell precursor frequencies directed against individual HLA-A and -B alloantigens. Journal of Immunological Methods 1989; 121: 39.
21. Roep BO, Kalian AA, Duinkerken G, et al. T cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes 1995; 44: 278.
22. Roep BO, Arden SD, de Vries RRP, et al. T cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature 1990; 345: 632.
23. Roep BO, Kalian AA, Hazenbos WL, et al. T cell reactivity to 38 kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes. Lancet 1991; 337: 1439.
24. Atkinson MA, Kaufman DL, Campbell L, et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992; 339: 458.
25. Worsaae A, Hejnaes K, Moody A, et al. T cell proliferative responses to glutamic acid decarboxylase-65 in IDDM are negatively associated with HLA DR3/4. Autoimmunity 1995; 22: 183.
26. Vandewalle CL, Decraene T, Schuit FC, et al. Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type I (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry. Diabetologia 1993; 36: 1155.
27. Gorus FK, Goubert P, Semakula C, et al. IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 1997; 40: 95.
28. Vandewalle CL, Falorni A, Lernmark A, et al. Associations of GAD65 - and IA-2 autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. The Belgian Diabetes Registry. Diabetes Care 1997; 20: 1547.
29. + T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplantation 1991; 52: 284.
30. van Besouw NM, Vaessen LM, Daane CR, et al. Peripheral monitoring of direct and indirect alloantigen presentation pathways in clinical heart transplant recipients. Transplantation 1996; 61: 165.
31. Bhargava R, Senior PA, Ackerman TE, et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004; 53: 1311.